Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TARS1 | P26639 | 2/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26090156 | 1.00 | HTR2B (0.35) | HTR2BHTR2CADORA3ADORA1ADRA2B | |
| SCHEMBL16987222 | 0.86 | TARS1 (0.38) | ADORA1TARS1 | |
| SCHEMBL29435121 | 0.86 | TARS1 (0.38) | ADORA1TARS1 | |
| SCHEMBL28564130 | 0.86 | TARS1 (0.38) | ADORA1TARS1 | |
| SCHEMBL29238711 | 0.86 | HTR2B (0.34) | HTR2BHTR2CADORA3ADRA2BHTR2A | |
| SCHEMBL29043762 | 0.85 | KDM4E (0.31) | HTR2BHTR2CKDM4EPKM | |
| SCHEMBL29407144 | 0.85 | KDM4E (0.31) | HTR2BHTR2CKDM4EPKM | |
| SCHEMBL31192291 | 0.81 | HTR2C (0.31) | HTR2BHTR2CKDM4EPKM | |
| SCHEMBL28521252 | 0.81 | HTR2C (0.31) | HTR2BHTR2CKDM4EPKM | |
| SCHEMBL28894185 | 0.79 | ADORA3 (0.54) | ADORA3ADORA1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2025151711-A1 | NUCLEIC ACID VACCINES TARGETING METHANOGENS | Arkea Bio Corp. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4554616-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2024233308-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| EP-4437125-A1 | RNA AND DNA ANALYSIS USING ENGINEERED SURFACES | Alida Biosciences, Inc. (US) | 2024-10-02 | — | — | EP | claimed |
| WO-2024123812-A1 | FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | SHATTUCK LABS, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| WO-2024097875-A1 | FUSION PROTEINS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS | SHATTUCK LABS, INC. (US) | 2024-05-10 | — | — | WO | claimed |
| WO-2024015366-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2024-01-18 | — | — | WO | claimed |
| WO-2023178182-A1 | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION | 10X GENOMICS, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| EP-4244389-A1 | METHOD | Ulifetec SAS (FR) | 2023-09-20 | — | — | EP | claimed |
| WO-2023097295-A1 | RNA AND DNA ANALYSIS USING ENGINEERED SURFACES | ALIDA BIOSCIENCES, INC. (US) | 2023-06-01 | — | — | WO | claimed |
| WO-2022101440-A1 | METHOD | ULIFETEC SAS (FR) | 2022-05-19 | — | — | WO | claimed |
| WO-2026107055-A1 | HEPATITIS B VIRUS VACCINE AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122070366-A | Cyclic RNA compositions and methods | 欧纳医疗公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122029278-A | Constructs, methods and uses for the preparation of circular RNAs | 上海环码生物医药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4735033-A2 | MRNA-ENCODED TAT WITH ATTENUATED CYTOTOXICITY FOR HIV AND SIV LATENCY REVERSAL | The Trustees of the University of Pennsylvania (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2022081694-A1 | IN VIVO TARGETING OF FIBROSIS BY ANTI-CD5-TARGETED FAP-CAR T MRNA-LNP | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022043551-A2 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | CUREVAC AG (DE) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022023559-A1 | NUCLEIC ACID ENCODED ANTIBODY MIXTURES | CUREVAC AG (DE) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022020785-A2 | GENE EDITING TO IMPROVE JOINT FUNCTION | ORTHOBIO THERAPEUTICS, INC. (US) | 2022-01-27 | — | — | WO | disclosed |